Matthew Bell (@matthew_r_bell) 's Twitter Profile
Matthew Bell

@matthew_r_bell

Postdoctoral Fellow @CHUVLausanne | @Kyttaro_Therapy lab @stjudegraduate PhD | interested in synthetic biology and cancer immunotherapy

ID: 1047135439730200576

calendar_today02-10-2018 14:45:18

89 Tweet

189 Followers

295 Following

Matthew Bell (@matthew_r_bell) 's Twitter Profile Photo

SynNotch-driven IL-2 allows T cells to overcome immunosuppression in solid tumors. Amazing work by Kole Roybal, Matthew Spitzer, and Wendell Lim UC San Francisco Parker Institute for Cancer Immunotherapy to design circuits to provide the right cytokine to the right cell at the right time science.org/doi/10.1126/sc…

Matthew Bell (@matthew_r_bell) 's Twitter Profile Photo

Danny Thomas was born 111 years ago. I have always been amazed by his radical vision to open a hospital in Memphis, TN in 1962 that would treat all patients equally. stjude.org/directory/t/da…

Daniel Connolly 〽️ (@danielconnolly) 's Twitter Profile Photo

We're heading into a tense night with the release of the video of #TyreeNichols fatal encounter with Memphis police. I covered similar deaths in Memphis for years. Here's a thread on why this case gained so much attention - and why it's _different_ from other cases. 1/18

St. Jude Research (@stjuderesearch) 's Twitter Profile Photo

“We've come up with a way to more efficiently and effectively bind and target cancer cells,” Peter Chockley says. Discover how his ‘molecular anchor’ improved chimeric antigen receptors against multiple cancer types in Nature Biotechnology. stjude.org/CAR-anchor-dom… #immunotherapy

“We've come up with a way to more efficiently and effectively bind and target cancer cells,” <a href="/PeterChockley/">Peter Chockley</a> says. Discover how his ‘molecular anchor’ improved chimeric antigen receptors against multiple cancer types in <a href="/NatureBiotech/">Nature Biotechnology</a>. stjude.org/CAR-anchor-dom… #immunotherapy
Matthew Bell (@matthew_r_bell) 's Twitter Profile Photo

Synapse tuning enhances CARs. Most impressive is tumor clearance with a single dose of CAR NK cells (No cytokines or other co-treatment) and functional persistance of NK cells to day 120 to reject tumor rechallenge. Great work Peter Chockley! nature.com/articles/s4158…

Lindsay Schwarz 🌧 (@lindsayschwarz) 's Twitter Profile Photo

presenting the first Schwarz lab preprint🎉: A Novel Single Vector Intersectional AAV Strategy for Interrogating Cellular Diversity and Brain Function biorxiv.org/content/10.110… (1/n)

Jesus Corria-Osorio (@corriajesus) 's Twitter Profile Photo

Delighted to share our more recent work about IL-2-related, non canonical , synthetic CD8 T cell states, now published in ⁦Nature Immunology⁩ . Huge thanks to ⁦George Coukos⁩ , ⁦Santiago Carmona 🧬 🖥️⁩ , ⁦Melita Irving⁩ and the whole team. nature.com/articles/s4159…

Veera Rajagopal  (@doctorveera) 's Twitter Profile Photo

A mind-blowing paper has come out today in nature In 2016, JC Venter Institute scientists trimmed a bacterial genome to its barest minimum required for life to synthesize what they called a "minimal genome" (science.org/doi/10.1126/sc…). Today, a group of scientists from

A mind-blowing paper has come out today in <a href="/Nature/">nature</a>  

In 2016, JC Venter Institute scientists trimmed a bacterial genome to its barest minimum required for life to synthesize what they called a "minimal genome" (science.org/doi/10.1126/sc…). 

Today, a group of scientists from
Matthew Bell (@matthew_r_bell) 's Twitter Profile Photo

If you want to learn more about our work on engineered cytokine receptors for CAR T cell therapy, check out the "Behind the Paper" on our recent Nature Biomedical Engineering article communities.springernature.com/posts/engineer…

Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team Center for Cell and Gene Therapy and beyond nature.com/articles/s4301…